Results 161 to 170 of about 105,114 (279)

Pharmacokinetic and pharmacodynamic sub-study of trans-arterial vs. intravenous gemcitabine in the TIGeR-PaC phase 3 clinical trial. [PDF]

Cancer Chemother Pharmacol
Novelli PM, Zervos EE, Zureikat AH, Pishvaian MJ, Meredith K, Hatoum H, Nazemzadeh R, Laroia S, Kasi P, Bingham J, Agah R.   +10 more
europepmc   +1 more source

Pancreatic Panniculitis as the First Presentation of Pancreatic Adenocarcinoma

JEADV Clinical Practice, EarlyView.
Claudine Howard‐James, Graham Woods, Ian McDonald   +2 more
wiley   +1 more source

Thrombocytosis and tumour distribution predict outcome in dogs with hepatocellular carcinoma: A multi‐institutional retrospective analysis

Veterinary Record, EarlyView.
Abstract Background Hepatocellular carcinoma (HCC) is the most common canine hepatobiliary tumour. This study aimed to determine which criteria influenced outcome of HCC in a modern population of dogs across eight institutions. Methods The medical records of 106 dogs with HCC were retrospectively reviewed.
Emily A. Janik, MacKenzie A. Pellin, Dawn M. Clarke   +2 more
wiley   +1 more source

Engineered Natural Killer Cell Derived-Extracellular Vesicles: An Acellular Immunotherapy with Cytotoxic Effects in SNU-1079 Human Cholangiocarcinoma Cells. [PDF]

Mol Pharm
Gondaliya P, Zinn DA, Sayyed AA, Driscoll J, Yan IK, Mensali N, Wälchli S, Patel T.   +7 more
europepmc   +1 more source

Diffuse Skin Sclerosis in a Patient With Lung Cancer

JEADV Clinical Practice, EarlyView.
Anna‐Sophia Leven, Eva Hadaschik, Alpaslan Tasdogan   +2 more
wiley   +1 more source

Peptide‐directed nanovehicles enabling tumor‐selective ROS amplification and antitumor immunity

VIEW, EarlyView.
Cancer cells are vulnerable to oxidative stress, yet exploit immune tolerance to escape destruction. In contrast, their metabolic profile is markedly altered to support rapid proliferation, accompanied by elevated production of reactive oxygen species (ROS).
Manuela Calin, Galyna Bila, Ileana Manduteanu, Rostyslav Bilyy   +3 more
wiley   +1 more source

Breast Skin Lesions in a 79‐Year‐Old Woman

JEADV Clinical Practice, EarlyView.
Javier Lorenz‐Dolz, Fátima Mayo‐Martínez, Andrea Díez Santandreu, Onofre Sanmartín Jiménez, Ruggero Moro   +4 more
wiley   +1 more source

Angiogenesis‐associated immune genes as prognostic markers and predictors of immunotherapy response in pancreatic ductal adenocarcinoma

VIEW, EarlyView.
Pancreatic ductal adenocarcinoma exhibits marked angiogenic and immune heterogeneity. We identified 28 angiogenesis‐associated immune genes and developed a seven‐gene AIGScore model comprising FGF2, ADGRB3, MMP2, TYMP, VASH1, VEGFD, and ITGAV. A high AIGScore was associated with poor survival, an immunosuppressive tumor microenvironment, and reduced ...
Qing Chang, Qian Wang, Xiumei Jiang, Yongmei Yang, Ailin Qu   +4 more
wiley   +1 more source

Adenylosuccinate lyase in pancreatic ductal adenocarcinoma chemoresistance: from purine metabolism to metabolic vulnerability. [PDF]

Cancer Drug Resist
Hsu TW, Su CM, Su YH, Liao PH, Saengboonmee C, Wang WY, Chen HA.   +6 more
europepmc   +1 more source

Palbociclib in the Treatment of HR+/ HER2‐ Advanced or Metastatic Breast Cancer in Australia: A Real‐World Retrospective Analysis

Asia-Pacific Journal of Clinical Oncology, EarlyView.
This study investigated the real‐world use of CDK4/6 inhibitors in Australian patients with HR+/HER2‐ advanced or metastatic breast cancer, providing data on patient demographics, treatment patterns, and outcomes with palbociclib. ABSTRACT Background There is limited real‐world data on the use of CDK4/6 inhibitors in Australian patients with HR+/HER2 ...
Louise Nott, Eugene Moylan, Maree Colosimo, Giles Stratton, Thomas Chiu, Mahsa H. Kouhkamari, Maureen Hitschfeld, Jessica Michie, Richard De Boer   +8 more
wiley   +1 more source